Bronte Capital Management’s NovaBridge Biosciences American Depositary Shares NBP Stock Holding History

Bronte Capital Management’s Portfolio NBP Stock Details NBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.8K	Buy	+11,192	New	+$22.8K	﹤0.01%	54

Other funds holding NBP

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACM

AIHC Capital Management Central $104M AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bronte Capital Management's NBP Position: Q2 2026 in Review

Bronte Capital Management opened a new position in NovaBridge Biosciences American Depositary Shares (NBP) in Q2 2026: 11,192 shares worth $21.8K. The stake represents ﹤0.01% of the portfolio and ranks #54 among its holdings.

49 funds tracked by Wall St. Rank hold NBP as of Q2 2026.

Bronte Capital Management held 11,192 shares of NovaBridge Biosciences American Depositary Shares worth $21.8K as of Q2 2026.
NovaBridge Biosciences American Depositary Shares was a new Bronte Capital Management position in Q2 2026.
NovaBridge Biosciences American Depositary Shares made up ﹤0.01% of Bronte Capital Management's portfolio in Q2 2026, its #54 holding.
49 funds tracked by Wall St. Rank held NovaBridge Biosciences American Depositary Shares as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.